WORTH A TRY? –
Dec. 9, 2025 – Results showed meaningful gains across the board. Depression scores fell by an average of 4.6 points, shifting participants from moderate to mild severity. Anxiety dropped by 4.8 points and well-being rose by 10.7 points. No serious adverse events occurred during sessions, A new study has found notable improvements in mental health among participants who underwent legal, supervised sessions with psychedelics in Oregon, the first state to legalize such services for adults. Published by Osmind, a mental health research and electronic health record company, the study analyzed treatment outcomes from individuals seeking relief from depression and anxiety under Measure 109 in Oregon. This 2020 voter-approved initiative decriminalized psilocybin, the psychoactive compound in psychedelic mushrooms, for therapeutic use by adults over 21 in state-licensed centers. While clinical trials have hinted at psilocybin’s potential at scale, this report offers early evidence from a commercial setting.
The Osmind study relies on voluntary self-reports, making it “naturalistic” research that captures how these services perform outside the strict protocols of randomized trials (measuring outcomes through self-reported surveys is standard practice in real-world scientific research).
